Crizotinib US FDA Label
- Compound: 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
- Description: Crizotinib is a 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) It has a role as an antineoplastic agent, a biomarker and an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor. It is an enantiomer of an ent-crizotinib.
- Brand Name:
- Code(s): PF2341066
- Approved:
- Kinase Class: RY
- Inhibitor Type: I ½B
- Literature (PubMed): 0
- Target(s): ALK receptor tyrosine kinase , Macrophage stimulating 1 receptor , MET proto-oncogene, receptor tyrosine kinase , ROS proto-oncogene 1, receptor tyrosine kinase
- Disease(s): anaplastic large cell lymphoma , inflammatory myofibroblastic tumor , non-small-cell lung carcinoma